VYNE Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019	2018
Market Capitalization	35	33	9	55	265	111	96
Market Cap Growth	-	273.57%	-84.05%	-79.42%	138.35%	16.26%	-
Enterprise Value	-58	-61	-22	12	241	72	-41
PE Ratio	-1.14	-1.14	-0.37	-0.74	-1.04	-1.17	-1.29
PS Ratio	83.13	76.70	18.25	58.63	12.64	251.21	26.63
PB Ratio	0.40	0.37	0.28	1.12	7.08	6.33	0.73
P/FCF Ratio	-1.28	-1.28	-0.30	-0.97	-1.93	-1.50	-1.38
P/OCF Ratio	-1.28	-1.28	-0.30	-0.97	-1.93	-1.52	-1.39
EV/Sales Ratio	-142.86	-142.86	-46.69	12.98	11.46	163.41	-11.27
EV/EBITDA Ratio	2.13	2.13	0.96	-0.18	-0.96	-0.77	0.55
EV/EBIT Ratio	2.13	2.13	0.96	-0.18	-0.96	-0.77	0.55
EV/FCF Ratio	2.39	2.39	0.76	-0.21	-1.75	-0.97	0.59
Debt / Equity Ratio	0.00	0.00	-	0.01	0.93	1.96	-
Debt / EBITDA Ratio	-0.01	-0.01	-	-0.01	-0.14	-0.37	-
Debt / FCF Ratio	-0.01	-0.01	-	-0.01	-0.25	-0.46	-
Quick Ratio	12.38	12.38	3.31	2.74	3.46	2.51	14.28
Current Ratio	12.73	12.73	4.10	3.43	4.01	2.61	14.62
Asset Turnover	0.01	0.01	0.01	0.01	0.17	0.00	0.02
Interest Coverage	-	-	-	-12.15	-57.27	-102.53	-
Return on Equity (ROE)	-79.10%	-79.10%	-52.90%	-106.50%	-448.20%	-118.10%	-49.30%
Return on Assets (ROA)	-64.20%	-64.20%	-44.80%	-68.00%	-207.40%	-91.00%	-46.20%
Return on Capital (ROIC)	-32.89%	-32.89%	-109.91%	-79.43%	-349.41%	-184.21%	-57.44%
Earnings Yield	-80.72%	-87.49%	-266.62%	-134.33%	-96.35%	-85.53%	-77.48%
FCF Yield	-71.89%	-77.92%	-335.42%	-103.26%	-51.72%	-66.87%	-72.32%
Buyback Yield / Dilution	-222.44%	-222.44%	-11.44%	-58.75%	-282.06%	-31.22%	-406.33%
Total Shareholder Return	-222.44%	-222.44%	-11.44%	-58.75%	-282.06%	-31.22%	-406.33%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).